Stef Heylen, MD, is the Managing Director of Heygieia Consulting BV, based in Belgium. He is a Board Member of the University Hospital UZA, Antwerp and the General Hospital AZ Turnhout. He also represents the Belgian Federal Investment Company FPIM on the Board of two clinical-stage biotech companies: ExeVir Bio and reMYND.

Stef retired in 2020 from Johnson & Johnson as CEO of Janssen Pharmaceutica NV, Belgium and as COO for Janssen R&D Worldwide. In these positions, he was a member of the Johnson & Johnson Pharmaceuticals Executive Committee and Chairman of the Management Board of Janssen Pharmaceutica NV. Stef has 35+ years of drug development and executive management experience. His expertise extends over a wide range of areas: the development of small molecules, monoclonal antibodies, and vaccines; clinical research in neuroscience and infectious diseases; regulatory affairs, drug safety, medical affairs, development operations, project/portfolio and general management. Stef obtained his M.D. at the University of Leuven, Belgium, and the Prince Leopold Institute for Tropical Medicine in Antwerp, Belgium.

Stef has a passion for sustainable development and global public health. He is also a mentor for “Duo for a Job”, an intergenerational mentoring program for young people with a recent migration background.